负压封闭吸引对结核术后难愈性创面中相关因子表达及预后的研究

目的 探讨应用负压封闭引流(VSD)治疗结核术后出现难愈性创面的患者,研究其相关因子的表达及预后。方法 选取2016年1月-2022年5月我院胸外科结核术后出现伤口愈合不良的患者76例,按数字表格法分为观察组和对照组,每组38例,观察组接受VSD治疗,对照组接受外科换药治疗,在治疗前和治疗后第7天用ELISA法测定血清中TNF-α、IL-4、IL-8、IL-10的含量和伤口肉芽组织中TGF-β1、VEGF、HIF-1α的含量及伤口愈合拆线时间。结果 比较两组治疗前TNF-α、IL-4、IL-8、IL-10及TGF-β1、VEGF、HIF-1α水平,差异无统计学意义(P>0.05)。治疗后第7天检测,TNF-α、IL-8较治疗前均降低,其中观察组较对照组降低更明显(P<0.05);IL-4、IL-10较治疗前均升高,其中观察组较对照组升高更明显(P<0.05);TGF-β1、VEGF较治疗前均升高,其中观察组较对照组升高更明显(P<0.05);HIF-1α较治疗前均降低,其中观察组较对照组降低更明显(P<0.05)。观察组愈合拆线时间较对照组明显缩短,差异有...     

唑来膦酸注射液联合降钙素治疗老年骨质疏松的疗效及其对血清IL-6、TNF-α水平的影响

目的探讨唑来膦酸注射液联合降钙素治疗老年性骨质疏松的疗效及对血清白细胞介素(IL)-6、肿瘤坏死因子(TNF)-α水平的影响。方法选择老年性骨质疏松患者120例,根据随机数字法分为对照组(C组)和观察组(O组),每组60例。C组在基础治疗的基础上给予降钙素治疗,O组在C组治疗的基础上给予唑来膦酸治疗。分别于治疗前和治疗后(4 w后),采用视觉模拟评分法(VAS)评估患者腰背部疼痛,采用双能X线骨密度仪测定患者腰椎(L2~4)骨密度值,采用酶联免疫吸附试验(ELISA)测定血清IL-6、TNF-α水平。结果治疗前,两组腰背部VAS评分、腰椎骨密度及血清IL-6、TNF-α水平差异无统计学意义(P>0.05)。与本组治疗前比较,治疗后两组腰背部VAS评分均明显降低(P<0.05),腰椎骨密度明显升高(P<0.05),血清IL-6、TNF-α水平显著降低(P<0.05);O组腰背部VAS评分明显低于C组(P<0.05),腰椎骨密度明显高于C组(P<0.05),血清IL-6、TNF-α水平明显低于C组(P<0.05)。腰背部VAS评分与血清IL-6、TNF-α水平呈正相关(P<0.05),腰椎骨密度与血清IL-6、TNF-α水平呈负相关(P<0.05)。结论唑来膦酸注射液联合降钙素治疗老年性骨质疏松疗效显著,可降低血清IL-6、TNF-α水平。     

不同激光光凝治疗时机联合玻璃体注射康柏西普治疗视网膜中央静脉阻塞继发黄斑水肿的有效性及安全性

目的探讨不同激光光凝治疗时机联合玻璃体腔注射康柏西普对视网膜中央静脉阻塞(CRVO)继发黄斑水肿(ME)的临床效果。方法选取缺血型CRVO患者100例(均为单眼患病),按照随机、双盲的方式分为研究组和对照组。其中研究组50例,先行玻璃体腔注射康柏西普,3 d后行激光光凝治疗,第2、3个月重复;对照组50例,间隔1个月注射康柏西普1针,连续注射3个月,并于最后1针康柏西普注射3 d后行激光光凝治疗,以后每周行激光治疗1次。观察并比较两组患者治疗前及治疗后不同时间点最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、玻璃体腔相关因子水平[血管内皮生长因子(VEGF)、白细胞介素(IL)-6、IL-8],同时比较两组治疗后相关并发症的发生率。结果治疗前,两组BCVA值相比差异无统计学意义(P0.05),治疗后,两组BCVA值均明显升高,研究组在治疗后1 w、1个月、2个月及3个月BCVA值均显著高于对照组(P0.05);治疗前,两组CMT值相比差异无统计学意义(P0.05),治疗后,两组CMT值均明显降低,研究组在治疗后1 w、1个月、2个月及3个月CMT值均明显低于对照组(P0.05);治疗前,两组玻璃体腔VEGF、IL-6及IL-8水平相比差异无统计学意义(P0.05),治疗后各指标均有下降,研究组IL-6水平在治疗后1 w、1个月、2个月及3个月均明显低于对照组(P0.05),VEGF及IL-8水平在治疗后1个月、2个月及3个月均明显低于对照组(P0.05),两组治疗后1 w VEGF及IL-8水平相比差异无统计学意义(P0.05);两组治疗后相关并发症的发生率相比差异无统计学意义(P0.05)。结论针对缺血型CRVO的患者,每次玻璃体注射康柏西普后3 d行激光光凝治疗,可明显促进患者视力恢复,改善黄斑水肿,降低玻璃体腔相关免疫因子水平。     

缬沙坦联合卡维地洛治疗对心力衰竭患者炎性因子及血管紧张素Ⅱ水平的影响

目的探讨缬沙坦对老年慢性心力衰竭患者血浆TNF-α、白细胞介素6(IL-6)和血管紧张素Ⅱ(AngⅡ)水平的影响。方法将95例老年慢性心力衰竭患者随机分为缬沙坦治疗组(对照组,48例)和缬沙坦联合卡维地洛组(联合治疗组,47例)。采用放射免疫法测定患者治疗前和治疗后3个月血浆TNF-α、IL-6和AngⅡ水平的变化。结果与治疗前比较,对照组、联合治疗组治疗3个月后血浆TNF-α、IL-6水平均有明显下降,差异有统计学意义(P<0.05);与对照组比较,联合治疗组TNF-α和IL-6下降更为显著,差异有统计学意义(P<0.05);两组AngⅡ水平在治疗前后差异无统计学意义(P>0.05)。结论单用缬沙坦或缬沙坦联合卡维地洛治疗慢性心力衰竭均能降低TNF-α、IL-6水平,心功能得到改善;缬沙坦联合卡维地洛治疗在降低TNF-α、IL-6水平和改善心功能方面优于单用缬沙坦。     

促红细胞生成素联合参附注射液对慢性心力衰竭合并贫血患者血清炎性因子水平和心功能的影响

目的探讨促红细胞生成素联合参附注射液对慢性心力衰竭(CHF)合并贫血患者血清炎性因子水平和心功能的影响。方法选取2015年7月—2016年6月三门峡市中心医院收治的CHF合并贫血患者76例,随机分为对照组和观察组,每组38例。在常规治疗基础上,对照组患者给予促红细胞生成素,而观察组患者给予促红细胞生成素联合参附注射液;两组患者均连续治疗两周。比较两组患者治疗前后血清血红蛋白(Hb)、游离脂肪酸(FFA)、炎性因子[包括白介素6(IL-6)、肿瘤坏死因子α(TNF-α)]水平及心功能指标[包括左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)]。结果治疗前两组患者血清Hb、FFA水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清Hb水平高于对照组,血清FFA水平低于对照组(P<0.05);治疗后两组患者血清Hb水平均高于治疗前,血清FFA水平均低于治疗前(P<0.05)。治疗前两组患者血清IL-6、TNF-α水平比较,差异无统计学意义(P>0.05);治疗后观察组患者血清IL-6、TNF-α水平低于对照组(P<0.05);治疗后两组患者血清IL-6、TNF-α水平均低于治疗前(P<0.05)。治疗前两组患者LVEF、LVEDD、LVEDV、LVESV比较,差异无统计学意义(P>0.05);治疗后观察组患者LVEF高于对照组,LVEDD、LVEDV、LVESV小于对照组(P<0.05);治疗后两组患者LVEF均高于治疗前,LVEDD、LVEDV、LVESV均小于治疗前(P<0.05)。结论促红细胞生成素联合参附注射液可有效纠正CHF合并贫血患者贫血状态,降低血清炎性因子水平并改善患者心功能。     

尤瑞克林对急性脑梗死患者血清CRP、IL-6及TNF-α的影响

目的观察尤瑞克林对急性脑梗死患者神经功能缺损评分(NDS)及血清C反应蛋白(CRP)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)的影响。方法 68例急性脑梗死患者随机分为对照组和观察组各34例,两组均给予常规治疗,对照组加用苦碟子注射液,观察组在对照组治疗基础上加用尤瑞克林。分别于治疗前及治疗后14d进行神经功能缺损评分,并检测血清CRP、IL-6及TNF-α水平。结果两组治疗后神经功能缺损评分及血清CRP、IL-6、TNF-α水平均逐渐下降(P<0.05),观察组下降更为明显(P<0.05)。结论尤瑞克林联合苦碟子注射液可降低急性脑梗死患者神经功能缺损程度、下调急性脑梗死患者血清CRP、IL-6及TNF-α水平,促进患者神经功能恢复。     

伐昔洛韦联合普瑞巴林对老年急性带状疱疹神经痛的疗效及对患者神经递质和细胞因子的影响

目的 探讨伐昔洛韦联合普瑞巴林对老年急性带状疱疹神经痛(PHN)的疗效及对患者神经递质和细胞因子的影响。方法 老年急性PHN患者96例,按照随机表法分为观察组与对照组各48例。对照组给予普瑞巴林治疗,观察组在对照组基础上结合伐昔洛韦片治疗。两组治疗疗程2 w。比较两组治疗2 w疗效,治疗前与治疗2 w疼痛视觉模拟评分(VAS)、匹兹堡睡眠质量指数(PSQI)量表、神经递质[P物质(SP)和β-内啡肽(β-EP)]和细胞因子[白细胞介素(IL)-6、IL-18和肿瘤坏死因子(TNF)-α]变化;记录两组不良反应。结果 观察组治疗总有效率显著高于对照组(P<0.05)。两组治疗2 w VAS和PSQI评分显著低于治疗前,且观察组显著低于对照组(P<0.05)。两组治疗2 w血清SP水平显著低于治疗前,而β-EP水平显著高于治疗前(P<0.05);且观察组血清SP水平显著低于对照组,而β-EP水平显著高于对照组(P<0.05)。两组治疗2 w血清IL-6、IL-18和TNF-α水平显著低于治疗前(P<0.05);且观察组显著低于对照组(P<0.05)。两组...     

补阳还五汤联合子午流注纳甲法治疗脑中风后遗症及对炎症因子的影响

目的探讨补阳还五汤联合子午流注纳甲法治疗脑中风后遗症病人的临床疗效以及对白细胞介素-10(interleukin-10,IL-10)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的影响。方法以2014年3月—2017年3月收入我院的96例脑中风后遗症病人为研究对象。随机分为对照组和研究组,每组48例。所有病人给予相同的基础治疗,对照组病人进行子午流注纳甲法针灸,研究组病人在对照组基础上服用补阳还五汤。治疗3个疗程。比较两组的临床疗效及治疗前后Fugl-Meyel评分、Bathel评分和美国国立卫生研究院卒中量表(NIHSS)评分,比较两组病人治疗前后IL-10、IL-6及TNF-α水平。结果研究组总有效率为95.83%,显著高于对照组的81.25%(P<0.05)。治疗前两组各指标差异无统计学意义(P>0.05)。治疗后,两组病人的Fugl-Meyel评分和Bathel评分均显著升高(P<0.01),NIHSS评分均显著降低(P<0.01),且研究组Fugl-Meyel评分和Bathel评分均显著高于对照组(P<0.01),NIHSS评分显著低于对照组(P<0.01)。治疗后,两组病人血清IL-10显著升高(P<0.01),IL-6及TNF-α水平均显著下降(P<0.05),且研究组IL-10高于对照组(P<0.05),IL-6及TNF-α显著低于对照组(P<0.05)。结论补阳还五汤联合子午流注纳甲法可以有效改善脑中风后遗症病人的临床症状,提高其运动功能和生活质量,改善神经功能缺损,同时降低血清IL-6和TNF-α水平,升高IL-10水平,减轻炎症反应,改善机体免疫平衡。     

加味血府逐瘀汤对冠心病血瘀证病人IL-6、VCAM-1、TNF-α表达的影响

目的观察加味血府逐瘀汤对冠心病血瘀证病人白细胞介素6(IL-6)、血管内皮细胞黏附因子1(VCAM-1)、肿瘤坏死因子-α(TNF-α)的影响。方法选取冠心病气虚证病人32例为对照组,冠心病血瘀证病人30例为治疗组,对照组给予常规西药治疗,治疗组给予常规西药联合加味血府逐瘀汤治疗,两组均治疗2周。观察并比较治疗前后两组临床疗效,中医证候改善情况,生化指标及IL-6、VCAM-1、TNF-α变化。结果治疗组总有效率为90.00%,对照组为71.88%,两组比较差异有统计学意义(P<0.05)。治疗后,治疗组胸痛、心悸、气短及总积分较治疗前降低(P<0.01),对照组胸痛、气短及总积分较治疗前降低(P<0.01);治疗后,两组总积分比较差异有统计学意义(P<0.01)。治疗前,治疗组血清IL-6水平高于对照组(P<0.01);治疗后,治疗组IL-6水平较治疗前下降,且治疗组IL-6降幅大于对照组(P<0.05);两组治疗后VCAM-1、TNF-α较治疗前降低(P<0.05),但两组治疗后比较,差异无统计学意义(P>0.05)。结论冠心病血瘀证病人较气虚证病人血管炎症反应更严重,加味血府逐瘀汤具有抗炎作用。     

丁苯酞注射液联合依达拉奉对老年急性脑梗死患者细胞因子、血管内皮功能和氧化应激的影响

目的探讨丁苯酞注射液联合依达拉奉对老年急性脑梗死患者细胞因子、血管内皮功能和氧化应激的影响。方法选取120例老年急性脑梗死患者,随机分为观察组与对照组各60例。观察组采用丁苯酞注射液联合依达拉奉注射液治疗,对照组采用依达拉奉注射液治疗。两组疗程均为14 d。比较两组治疗14 d总有效率;治疗前与治疗14 d细胞因子[肿瘤坏死因子(TNF)-α、白介素(IL)-6和IL-8]、血管内皮功能[一氧化氮(NO)和血管内皮生长因子(VEGF)]、氧化应激[丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)和超氧化物歧化酶(SOD)]和美国国立研究院脑卒中量表(NIHSS)评分。结果观察组治疗14 d总有效率显著高于对照组(χ^2=8.640,P<0.05)。观察组治疗14 d血清TNF-α、IL-6和IL-8水平显著低于对照组(t=7.459、9.320、13.993,P<0.05)。观察组治疗14 d血清NO水平显著高于对照组,而VEGF水平显著低于对照组(t=10.637、29.253,P<0.05)。观察组治疗14 d血清MDA水平显著低于对照组,而GSH-Px和SOD水平显著高于对照组(t=10.127、9.575、22.761,P<0.05)。观察组治疗14 d NIHSS评分显著低于对照组(t=13.540,P<0.05)。结论丁苯酞注射液联合依达拉奉注射液对老年急性脑梗死患者疗效明显,可减轻患者炎症反应,改善患者血管内皮功能和氧化应激水平。     

Usefulness of procalcitonin for diagnosis of infective endocarditis

The aim of this study was to evaluate the accuracy of procalcitonin (PCT) in predicting infective endocarditis (IE). 23 adult patients with IE, 30 patients with sepsis and 30 with tick-borne encephalitis were included in this prospective study. The PCT serum level, C-reactive protein (CRP), total leukocyte, and immature polymorphonuclear (PMN) cell counts were determined on admission, prior to the institution of antibiotic therapy, and compared according to the diagnosis. The median PCT level in patients with IE endocarditis was 0.81 ng/ml, in patients with sepsis it was 43.74 ng/ml, and in the group with viral infection it was 0.25 ng/ml (P < 0.001). The highest PCT level was found in patients with Staphylococcus aureus endocarditis. The area under the receiver operating characteristic curve that used PCT to predict IE was 0.722 (95% CI 0.572–0.873), compared with 0.909 (95% CI 0.829–0.989) for CRP, 0.699 (95% CI 0.551–0.846) for immature PMN cell count, and 0.619 (95% CI 0.468–0.770) for leukocyte count. Our study fails to demonstrate superiority of PCT as a diagnostic laboratorial parameter in predicting IE compared to CRP.     

慢型、潜在型克山病患者的血管内皮功能观察

目的观察山东省慢型、潜在型克山病患者的临床特点和血管内皮功能,探讨机体内皮功能失调与克山病发生发展的关系。方法选择慢型、潜在型克山病患者57人、病区健康人34人,分别采集清晨空腹血检测ET、NO、NOS、iNOS及cNOS含量及活性。结果(1)克山病患者ET水平明显高于病区健康人(P<0.01);心功能越差,ET升高越明显(P<0.01);(2)NO和NOS含量,潜在型、慢型克山病均明显高于病区健康人(P<0.01);慢型高于潜在型(P<0.01);iN-OS含量克山病患者也高于病区健康人(P<0.05);慢型克山病高于潜在型克山病(P<0.05)。结论ET、NO水平的变化可能作为一种中间环节参与了克山病的发病机制;心功能不同,血浆ET、NO升高的程度也不同;ET、NO可作为克山病病情严重程度的预测指标。     

Papillomavirus Infectious Pathways: A Comparison of Systems

The HPV viral lifecycle is tightly linked to the host cell differentiation, causing difficulty in growing virions in culture. A system that bypasses the need for differentiating epithelium has allowed for generation of recombinant particles, such as virus-like particles (VLPs), pseudovirions (PsV), and quasivirions (QV). Much of the research looking at the HPV life cycle, infectivity, and structure has been generated utilizing recombinant particles. While recombinant particles have proven to be invaluable, allowing for a rapid progression of the HPV field, there are some significant differences between recombinant particles and native virions and very few comparative studies using native virions to confirm results are done. This review serves to address the conflicting data in the HPV field regarding native virions and recombinant particles.     

三七有效组分Rx对兔动脉粥样硬化的实验研究

目的：探讨三七有效组分R。对兔动脉粥样硬化的影响。方法：40只雄性新西兰大白兔随机分成正常对照组、高脂模型组、三七总皂甙组三七有效组分Rx高荆量组、三七总皂甙组三七有效组分Rx低刺量组，喂饲12周后同时处死．分别测定血一氧化氮(NO)、内皮素(ET)、PAI、t—PA、血浆脂质过氧化物、红细胞内超氧化物歧化酶(SOD)，并行主动脉壁形态学、主动脉壁光镜、透射电镜观察。结果：三七有效组分Rx高、低剂量组明显升高血NO、t—PA，降低血清ET、PAI水平，抗脂质过氧化，提高红细胞内SOD活性。大体形态、光镜、电镜显示，三七有效组分Rx高、低剂量组能减轻动脉粥样硬化病变程度，减少泡沫细胞层数。结论：三七有效组分Rx有干预动脉粥样硬化的作用。     

前列腺干细胞抗原在人前列腺癌组织中的表达及意义

目的 探讨前列腺干细胞抗原（PSCA）在人前列腺癌（PCa）和正常前列腺（NP）、良性前列腺增生（BPH）组织中的表达及其与临床分期、病理分级的关系。方法 采用免疫组织化学（IHC）链霉菌过氧化物酶法（SP法）检测26例人PCa石蜡包埋标本、10例BPH患者的前列腺切除标本及3例NP标本中PSCA的表达。结果 PSCA在PCa组织中表达阳性率为96．2％，其中强阳性率为88．5％。NP组织阳性率为66．7％（均为弱阳性）。BPH组织阳性率为70．0％（均为弱阳性）。PCa与NP、BPH组织表达水平差异有显著性意义（P〈0．01），BPH与NP组织表达水平无统计学意义（P〉0．05）。PSCA在PCa组织主要表达于癌细胞，细胞间质和肌肉组织均无表达；NP及BPH组织表达则定位于前列腺上皮的基底细胞层。PSCA表达水平与PCa临床分期、病理分级均无相关性（P〉0.05）。结论 PSCA是一个新的细胞表面抗原，可能在PCa的诊断、免疫治疗等方面具有广阔的应用前景。     

Relevance of Endocavitary Structures in Ablation Procedures for Ventricular Tachycardia

Endocavitary Structures and Ventricular Tachycardia Ablation. Background: Radiofrequency (RF) ablation for ventricular tachycardia (VT) has high failure rates. Whether endocavitary structures (ECS) such as the papillary muscles (PMs), moderator bands (MBs), or false tendons (FTs) impact VT ablation is unknown. Methods and Results: We retrospectively reviewed records of 190 consecutive patients presenting for VT ablation and identified 46 (24%) where ECS affected ablation. In 31 of 46 patients (67%), the ECS created difficulty with catheter manipulation (n = 20), interpretation of pace map data (n = 7), or with accurately defining a scar (n = 4). In 15 of 46 (33%), specific mapping and RF energy delivery targeting the ECS itself was necessary to eliminate the arrhythmia. Detailed electroanatomic mapping was performed in 11 of 15 (73%), noncontact mapping in 3 of 15 (20%), multielectrode catheter mapping in 1 of 15 (7%), and intracardiac ultrasound in 14 of 15 (93%) patients. The ablated ECS was a PM in 5 of 15, the MB in 7 of 15, and an FT in 3 of 15. The arrhythmogenic substrate on the ECS was a focus of automatic tachycardia in 9 of 15 and the slow zone responsible for reentrant arrhythmia in the remaining 6 of 15. Successful elimination of tachycardia without recurrence was obtained in all 15 cases. There was no evidence of valvular damage or disruption of the valvular apparatus. Conclusion: During VT ablation procedures, ECS should be considered for specific mapping and targeted ablation. Once recognized, these structures can be successfully targeted for ablation without valve damage. (J Cardiovasc Electrophysiol, Vol. 21, pp. 245–254, March 2010)     

降钙素原在医院获得性肺炎和呼吸机相关性肺炎的诊断和抗感染管理中的应用价值

医院获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)是我国现患率居第一位的医院感染性疾病。国内外相关指南相继进行了更新,旨在提高HAP/VAP诊断和治疗水平,改善患者的结局,但我们仍然面临诸多挑战。降钙素原(PCT)是较C反应蛋白(CRP)更特异的感染相关生物学标志物,对重症细菌感染和脓毒症具有反应快速、特异性高的优点,动态监测PCT可指导HAP/VAP的诊断及抗菌药物治疗的疗程。     

Palliative management of refractory dyspnea in COPD

COPD is a progressive illness with worldwide impact. Patients invariably reach a point at which they require palliative interventions. Dyspnea is the most distressing symptom experienced by these patients; when not relieved by traditional COPD management strategies it is termed “refractory dyspnea” and palliative approaches are required. The focus of care shifts from prolonging survival to reducing symptoms, increasing function, and improving quality of life. Numerous pharmacological and non-pharmacological interventions can achieve these goals, though evidence supporting their use is variable. This review provides a summary of the options for the management of refractory dyspnea in COPD, outlining currently available evidence and highlighting areas for further investigation. Topics include oxygen, opioids, psychotropic drugs, inhaled furosemide, Heliox, rehabilitation, nutrition, psychosocial support, breathing techniques, and breathlessness clinics.     

Expression of membrane-type matrix metalloproteinases in synovial tissue from patients with rheumatoid arthritis or osteoarthritis

We investigated the expression of membrane-type matrix metalloproteinase (MT-MMP) and matrix metalloproteinase (MMP) mRNAs in synovial tissue from patients with rheumatoid arthritis (RA, n = 5) or osteoarthritis (OA, n = 5) by Northern blot analysis. Northern analysis demonstrated strong expression of MT1-MMP, MT3-MMP, MMP-1, and MMP-3 and weak expression of MT2-MMP and MMP-8 in synovial tissue from patients with RA or OA. MT4-MMP was not detected. No significant difference was shown in the expression of MT-MMP mRNAs between RA and OA. Synovial tissue of RA or OA patients expressed MT-MMPs as well as MMPs. These results indicate that, in addition to MMPs, MT1-MMP, MT3-MMP, and probably MT2-MMP may play a role in the degradation of bone and cartilage matrix in RA and OA. Such information may provide a clue to the development of a novel therapeutic approach targeted on the prevention of joint destruction. Received: April 30, 2000 / Accepted: September 19, 2000     

Methemoglobin Forming Effect of Dimethyl Trisulfide in Mice

Abstract

Dimethyl trisulfide (DMTS) is a natural organic trisulfide that has been patented as a promising antidotal candidate against cyanide (CN). The primary mode of action of DMTS is as a sulfur donor that enables the conversion of CN to thiocyanate. Recently, it was discovered that DMTS is capable of oxidizing hemoglobin (Hb) to methemoglobin (MetHb) in vitro. The goal of these experiments was to measure the extent of DMTS-induced MetHb formation in vivo. In these experiments, intramuscular (IM) injections of formulated DMTS were administered to mice. Following the IM injection, blood was drawn and analyzed for MetHb using a rapid spectrophotometric method. Methemoglobin levels peaked in a dose-dependent manner between 20 and 30?min., and then began dropping. The highest MetHb levels measured for the 50, 100, 200 and 250?mg/kg doses of DMTS were respectively 3.28, 6.12, 9.69, and 10.76% MetHb. These experiments provide the first experimental evidence that IM administered DMTS generates MetHb in vivo and provide additional evidence for the presence of a secondary therapeutic pathway for DMTS - CN scavenging by DMTS-generated MetHb.